Vitamin D and Exercise to Improve Physical Function in Older Adults

Not Applicable

Completed

• Conditions: Sarcopenia; Mobility Limitation; Insulin Resistance; Cardiometabolic Health; Musculoskeletal - Other muscular and skeletal disorders; Diet and Nutrition - Obesity

• Registration Number: ACTRN12616000563460
• Lead Sponsor: Prof. Peter Ebeling

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-05-02
• Study Completion: 2020-07-03
• Last Update Posted: 2 May 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Community-dwelling; age 50-80 years; BMI 25-40 (overweight or obese); low vitamin D status (serum 25-hydroxyvitamin D [25OHD] less than or equal 49.9nmol/L); willing, and has GP approval, to complete a 12-week exercise intervention, willing to be randomised to either vitamin D or placebo.

Exclusion Criteria

Self-reported inability to unable to walk 400 metres non-stop unassisted (ie. without use of walking aids); non-English speaking; vitamin D supplementation greater than or equal to 1000 International Units/day; 4 weeks self-reported participation in a supervised exercise program targeted at weight loss or strength gains in the past six months; planning to be away from home for more than 2 weeks during the training phase; women who are pregnant or are trying to become pregnant; and self-reported diagnosis of: Progressive neurological disorders including Parkinson’s Disease and multiple sclerosis; schizophrenia or bipolar disorder; severe knee or hip osteoarthritis (awaiting a joint replacement) that would interfere with ability to complete functional tests; lung disease requiring regular use of supplemental oxygen; renal disease requiring dialysis, any other disorder of such severity that life expectancy is less than 12 months; and stroke, hip or knee replacement, spinal surgery, myocardial infarction or major heart surgery in the past 6 months. Also, use of medications contraindicated for vitamin D supplementation including: thiazide diuretics, cholestyramine, colestipol, corticosteroids, mineral oil, orlistat, phenytoin, barbiturates, digitalis glycosides, and antacids (magnesium).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A clinically meaningful change in usual gait speed (mean: 0.10 m/s; SD 0.12 m/s) over a 2.44-metre course <br>[Baseline, 12 and 24 weeks]